SHAREHOLDER ALERT: Investigation of Solid Biosciences Inc. Announced by Holzer & Holzer, LLC
Holzer & Holzer, LLC is investigating whether certain statements made by Solid Biosciences, Inc. (“Solid Biosciences” or the
“Company”) (NASDAQ: SLDB) complied with federal securities laws. On February 7, 2019, the price of Solid Biosciences shares fell
significantly following the Company’s announcement of preliminary findings from IGNITE DMD, the Company’s Phase I/II dose-ascending
clinical trial evaluating the safety and efficacy of SGT-001 microdystrophin gene transfer for the treatment of Duchenne muscular
dystrophy (DMD).
If you purchased Solid Biosciences shares and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer,
Esq. at cholzer@holzerlaw.com or Marshall P. Dees, Esq. at mdees@holzerlaw.com, or by toll-free telephone at (888) 508-6832 to discuss your
legal rights.
Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders
and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the
firm is available through its website,
www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional
communication, and Corey D. Holzer is the attorney responsible for its content.
Corey D. Holzer, Esq.
(888) 508-6832 (toll-free)
cholzer@holzerlaw.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190207005617/en/